
Revolutionizing Cardiology: Ultromics Secures £41,400,000 in Funding
In an exciting move for the healthcare sector, Ultromics, a pioneering AI-driven cardiology firm based in Oxford, UK, has successfully raised £41,400,000 (GBP) in Series C funding. This substantial investment round was spearheaded by industry titans such as L&G, Allegis Capital, and Lightrock, alongside robust backing from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University. Notably, UChicago Medicine’s venture investment vehicle, UCM Ventures, and UPMC Enterprises also threw their weight behind this transformative company. With these new capital influxes, Ultromics is set to accelerate its operations and enhance vital research and development efforts in the realm of cardiovascular care.
Ultromics is at the forefront of revolutionizing heart disease diagnostics through its innovative EchoGo® platform, which integrates artificial intelligence with echocardiography.
This groundbreaking tool, developed in collaboration with the NHS and Mayo Clinic, empowers clinicians by facilitating the early and precise detection of complex heart diseases using routine ultrasound scans. To date, Ultromics has analyzed over 430,000 echocardiograms, with remarkable clinical outcomes. In fact, studies show that EchoGo improves the detection of heart failure with preserved ejection fraction (HFpEF) by an impressive 73.6% compared to conventional clinical risk scores, providing a potent offering for both healthcare providers and patients alike.
Ultromics’ continued commitment to innovation is evidenced by its latest diagnostic model for cardiac amyloidosis. This model has undergone rigorous validation in a global study comprising 18 prominent institutions and has been featured in the European Heart Journal. The findings reveal its ability to outshine existing clinical risk scores, significantly enhancing disease differentiation from similar conditions. For startup founders and investors in the healthcare space, Ultromics represents a compelling investment opportunity, as it not only demonstrates extensive funding support but also a steadfast trajectory towards redefining cardiovascular healthcare through intelligent technology.
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
![]() L&G( ) Legal & General invests strategically across fintech, housing, climate and infra... London | ||||
![]() Allegis Capital( ) Palo Alto, US | ||||
![]() Lightrock( ) London | ||||
![]() Oxford Science Enterprises( ) The firm focuses on investing in Life Sciences, Health Tech, and Deep Tech, prim... Oxford | ||||
![]() Google Ventures( ) GV (Google Ventures), established in 2009, invests in technology-driven companie... London | ||||
![]() Blue Venture Fund( ) Boston, US | ||||
![]() | ||||
![]() UCM Ventures( ) Chicago, US | ||||
![]() UPMC Enterprises( ) Pittsburgh, US | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK